Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncotelic Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical issuer with oncology, rare-disease, AI-enabled research and drug-delivery assets. Recent Form 8-K reports cover material definitive agreements, including the TechForce Robotics joint development and licensing framework for AI-enabled GMP robotic systems using the PDAOAI platform, the completed Lunai Bioworks asset transaction involving nose-to-brain delivery patents, and financing arrangements tied to convertible debt and warrants.
OTLC filings also describe capital-structure and governance matters, including a performance-based restricted stock agreement involving Series A Preferred Stock, common-stock conversion terms, secured-note collateral and warrant issuances. Other filings include annual-results exhibits, late annual-report notices on Form 12b-25, and furnished updates on GMP Bio interests, Sapu Nano's Deciparticle nanomedicine platform, everolimus toxicology data and pipeline disclosures.
Oncotelic Therapeutics, Inc. reports that on July 13, 2026 it delivered a corporate presentation to its employees, directors, officers and advisors. The presentation, referred to as the “Corporate Presentation,” is provided as Exhibit 99.1 to the current report.
The company states that the information furnished under Section 8.01, including Exhibit 99.1, is being furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934. It also clarifies that this information is not incorporated by reference into any Securities Act or Exchange Act filing, except where specifically referenced. The report is signed on behalf of the company by Vuong Trieu, Ph.D., its Chief Executive Officer.
Oncotelic Therapeutics, Inc. approved equity incentives for directors, officers, employees and advisors by granting an aggregate 17,796 restricted stock units (RSUs) under Restricted Stock Unit Award Agreements. Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock.
The RSUs vest only if the company’s common stock is uplisted to a national stock exchange on or before June 30, 2027, or a later date if extended by the board, and the recipient continues service for six months after the uplisting. Otherwise, the RSUs automatically expire and are forfeited. Grants include 2,000 RSUs to CEO Vuong Trieu and 1,500 RSUs each to several senior executives. The awards are granted at no cost to recipients and rely on the private-offering exemption in Section 4(a)(2) of the Securities Act.
MAIDA ANTHONY E III reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. reported that director and Chief Medical Officer – Translational Medicine Anthony E. Maida III received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026 at no cost. Each RSU settles into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. The RSUs are subject to performance and time-based vesting, becoming eligible upon an uplisting of the company’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and the executive’s continued service for six months following the uplisting.
Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.
Shah Amit B. reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics CFO Amit B. Shah received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, which is itself convertible into common stock, if performance and time-based vesting conditions tied to a national-exchange uplisting are satisfied.
Trieu Vuong reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics reports that Chairman and CEO Trieu Vuong received a grant of 2,000 restricted stock units on July 10, 2026. Each RSU can settle into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, subject to performance- and time-based vesting. The RSUs vest only if the company uplists its common stock to a national securities exchange by June 30, 2027 (or a later board-approved date) and Vuong remains in service for six months after uplisting. After these reported holdings, Vuong owns 94,124,319 common shares directly and holds additional shares indirectly, including 6,872,529 through his spouse and 16,780,384 through Autotelic Inc.
Oncotelic Therapeutics, Inc. Chairman and CEO Dr. Vuong Trieu reported an open-market purchase of company stock. On July 1, 2026, he bought 240,000 shares of Common Stock at a price of $0.0431 per share in his individual capacity.
Following this transaction, Dr. Trieu directly owned 94,124,319 shares of Common Stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc., providing a view of both his direct and indirect ownership stakes.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a convertible promissory note with an aggregate gross principal amount of $178,410. The note carries a 12% original issue discount, bears interest at 12% per year, and matures on the earlier of one year from the agreement date, an acceleration after an Event of Default, or full prepayment.
The note is convertible into common stock at the lower of a fixed $0.06 per share or 85% of the lowest traded price over the 10 trading days before conversion, subject to adjustments. Oncotelic also issued 500,000 shares of common stock to Pacific Pier as commitment shares. If an Event of Default occurs, the principal and accrued interest become immediately due in cash at a 16% default interest rate. The note and shares were issued in a private offering relying on the Section 4(a)(2) exemption from Securities Act registration.
Oncotelic Therapeutics, Inc. director, chairman, CEO and ten percent owner Vuong Trieu reported open-market purchases of a total of 255,000 shares of common stock at $0.045 per share over three days in late June 2026. He bought 65,000 shares on June 22, 75,000 shares on June 23, and 115,000 shares on June 24 in his individual capacity. Following these purchases, his directly held stake rose to 93,884,319 shares. The filing also lists additional indirect holdings of common stock, including 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc. as of June 22.
Oncotelic Therapeutics, Inc. CFO Amit B. Shah bought additional company stock in the open market. On June 22, 2026, he purchased 20,000 shares of common stock at a price of $0.05 per share in his individual capacity. Following this transaction, he directly owns 378,837 shares of Oncotelic common stock.